Bicuspid aortic valve (BAV) stenosis is the most common congenital valve disease, affecting up to 2% of the population. Patients with BAV disease undergoing transcatheter aortic valve replacement (TAVR) account for 0.5%. In this context, TAVR data on BAV stenosis patients has been limited to observational studies on first generation valves that had resulted in<a href="https://solaci.org/en/2023/05/21/europcr-2023-tavr-in-patients-with-bicuspid-aortic-valve-stenosis/" title="Read more" >...</a>
Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear. The aim of this study was to assess events in patients undergoing TAVR with<a href="https://solaci.org/en/2023/05/17/europcr-2023-tavr-in-cardiogenic-shock/" title="Read more" >...</a>
The natural history of tricuspid regurgitation is associated to hospitalization for cardiac failure and mortality. This is why the AHA/ACC guidelines recommend surgery when the tricuspid fails during left valve surgical repair, because its slow progression is associated with high mortality (35%). Many of these patients are high risk and percutaneous intervention has surged as<a href="https://solaci.org/en/2023/05/12/latest-developments-in-tricuspid-regurgitation/" title="Read more" >...</a>
Coronary artery obstruction (CAO) after TAVR is rare, but it entails extremely high mortality (50% or more), especially after valve-in-valve (V-in-V) or when the coronary ostia are is too close to the valve annulus. This is why the BASILICA technique was developed (Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction).<a href="https://solaci.org/en/2023/05/04/basilica-a-complex-strategy-yet-safe/" title="Read more" >...</a>
Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its safety and efficacy at followup in low risk patients. At present we have 2-year data from the Evolute Low Risk, but the we lack information at longer followup. The study looked at 3-year followup of the Evolute Low<a href="https://solaci.org/en/2023/05/03/evolute-low-risk-at-3-years-promising-outcomes/" title="Read more" >...</a>
We are aware of sex related differences when it comes to comorbidities, physiopathology and disease evolution in patients with tricuspid regurgitation (TR). TR is more prevalent among women, whereas among men, coronary artery disease is more prevalent, with worse left ventricular ejection fraction and 10-year survival rate. Transcatheter tricuspid valve intervention (TTVIs) has surged as<a href="https://solaci.org/en/2023/04/26/sex-related-differences-in-clinical-outcomes-after-transcatheter-tricuspid-valve-intervention/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) has been proving its benefit in different scenarios for two decades now. However, in the field of self-expanding valves, one challenge has always been its high rate of pacemaker implantation compared with balloon-expandable devices and valvular replacement surgery. For this reason, the high implantation or Cusp Overlapping strategy was developed.<a href="https://solaci.org/en/2023/04/20/high-implantation-of-self-expanding-valves-in-the-aortic-position-or-cusp-overlapping-should-it-be-the-new-gold-standard/" title="Read more" >...</a>
Edge-to-edge treatment has proven to be a safe and effective technique in follow-up, decreasing mortality and hospitalizations for heart failure when a good result is achieved. The MitraScore was developed to assess the outcome at the end of the procedure. In that sense, results <3 represent mild mitral regurgitation, which would be related to lower<a href="https://solaci.org/en/2023/03/31/mitrascore-what-does-the-final-result-of-edge-to-edge-treatment-of-mitral-regurgitation-provide/" title="Read more" >...</a>
At present, surgical aortic valve replacement (SAVR) uses bioprostheses. However, when these fail, we are presented with a great challenge, seeing as repeat SAVR involves a higher risk. In this context, valve-in-valve (V-in-V TAVR) has surged as a very attractive alternative. Bioprosthesis fracture (BPF) is a new interesting strategy that has shown lower gradient and<a href="https://solaci.org/en/2023/03/28/when-is-it-best-to-fracture-a-bioprosthesis-in-tavr/" title="Read more" >...</a>
Secondary ischemic and non-ischemic mitral valve failure (SMR), produce left ventricle dilation, papillary muscle displacement, and impaired leaflet closure causing regurgitation. This will lead to ventricular function deterioration and bad prognosis. Edge-to-edge mitral valve repair with MitraClip has been shown safe and effective to treat SMR in the short term, but its evolution at 5<a href="https://solaci.org/en/2023/03/17/coapt-promising-5-year-outcomes/" title="Read more" >...</a>